Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT with or without Sintilimab for Small HCC
NCT06313190Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Apr 2024
- Primary completion
- Apr 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen University. Started Apr 2024; status: recruiting.
02
Drugs
sintilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06313190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06313190.